Although devascularization caused by antiangiogenic therapy limits tumor growth, the benefits of antiangiogenic therapy are often transient, with tumor growth typically resuming through adaptive responses that need further characterization. Recent reports indicate that hypoxia in tumor microenvironments induces autophagy, a lysosomal degradation pathway that may promote tumor cell survival. We investigated the hypothesis that antiangiogenic therapy leads to hypoxia, which induces tumor cell autophagy as a cytoprotective adaptive response promoting evasion to antiangiogenic therapy. We found that patient specimens from glioblastomas evasive to bevacizumab exhibited nearly 80% more hypoxia than did pretreatment specimens from the same patients. Hypoxia (1% oxygen) induced autophagy in several primary glioblastoma cells and cell lines. Selective autophagy occurred independent of HIF-1a/AMPK hypoxia-upregulated pathways, while nonselective autophagy depended on both. Autophagy inhibitors transitioned hypoxic glioblastoma cells from autophagy to nonapoptotic cell death. Patient specimens from glioblastomas evading antiangiogenic therapy expressed 55% more autophagy-related BNIP3 than did pretreatment specimens from the same patients, with BNIP3 expression localizing to the increased hypoxic areas seen in the glioblastomas that evaded antiangiogenic therapy. Human glioblastoma xenografts exhibited persistent growth inhibition when treated with autophagy inhibitor chloroquine plus antiangiogenic bevacizumab; chloroquine prevented the evasive hypoxia-associated growth seen with bevacizumab alone and reversed the more than 2-fold increased expression of autophagy mediator BNIP3 seen in xenografts growing during bevacizumab monotherapy. These findings suggest that hypoxia-mediated autophagy promotes tumor cell survival after antiangiogenic therapy, a novel adaptive response to antiangiogenic therapy that can be pharmacologically disrupted to allow antiangiogenic therapy to fulfill its therapeutic promise.
INTRODUCTION:
The benefits of antiangiogenic treatment in glioblastoma are unfortunately transient, with preclinical studies suggesting that tumors evade antivascular therapies through mechanisms like transcriptional upregulation. We performed gene expression analysis and immunohistochemistry comparing bevacizumab-evasive glioblastomas (BEGs) to their paired primary tumors. METHODS: We identified 16 bevacizumab-treated glioblastomas that progressed during treatment requiring surgery. Half were enhancing BEGs (EBEGs) and half nonenhancing BEGs (NBEGs). Microarray analysis and immunohistochemistry compared pre-bevacizumabtreatment gliomas and BEGs. Fresh tissue was used for Matrigel invasion assays and xenograft formation. RESULTS: Compared with their paired primary gliomas, EBEGs had unchanged vascularity and hypoxia with increased proliferation, while NBEGs had less vascularity, more hypoxia, and no change in proliferation. NBEGs were associated with a longer duration of antiangiogenic therapy before evasive growth. Microarray analysis revealed that BEGs upregulated genes associated with the mesenchymal glioblastoma subtype, including tyrosine kinase c-Met. Microarray analysis also revealed that NBEGs clustered distinctly from EBEGs. NBEGs expressed extracellular matrix interactions and invasion-related genes, while EBEGs expressed cell proliferation, immunosuppression, or edema-related genes. Matrigel invasion assays revealed more invasiveness in NBEGs than EBEGs. A xenograft established from an NBEG maintained refractory to the survival-promoting effect, vascular permeability, and increased blood volume on MRI associated with VEGF blockade. Growth of this xenograft was inhibited by a small molecule c-Met inhibitor. DISCUSSION: We found that BEGs upregulated transcription of mesenchymal subtype genes. We identified 2 radiographic growth patterns during evasion to antiangiogenic therapy. Enhancing tumors reacquired their pretreatment vessel density and expressed factors mediating inflammation, edema, and proliferation. Nonenhancing tumors arise after longer antiangiogenic treatment and grow despite maintained devascularization, likely because of increased invasiveness caused by factors like c-Met. Screening inhibitors of evasion to antiangiogenic therapy using xenografts like the one described here could allow antianigogenic therapy to fulfill its therapeutic promise.
AI-03. THE HCMV PROTEIN PP71 IS EXPRESSED IN PRIMARY HUMAN GLIOBLASTOMAS AND STIMULATES SECRETION OF THE PROANGIOGENIC CHEMOKINE STEM CELL FACTOR
Lisa A. Matlaf, Liliana Soroceanu, and Charles Cobbs; California Pacific Medical Center, San Francisco, CA Our laboratory was the first to demonstrate that the ubiquitous human pathogen cytomegalovirus (HCMV) is highly associated with the most common and deadly form of primary brain tumor, glioblastoma multiforme (GBM). Several studies have confirmed our findings; however, the role of HCMV in glioma pathogenesis is still unclear. We hypothesize that HCMV can act as a promoter of the neoplastic process in glioma by modulating the survival, invasive potential, angiogenic properties, DNA damage response, and immune evasion of tumor cells. The viral tegument protein pp71 (UL82) is a prime candidate for promoting the oncomodulatory effects of HCMV given its reported ability to degrade important cellular regulatory proteins and facilitate immune evasion. Using RT-PCR, Western blot, and immunofluorescence approaches, we identified pp71 expression in several primary GBM tissue samples and demonstrated that normal human neural precursor cells (NPCs) that were transduced with pp71 displayed increased expression and secretion of the proangiogenic cytokine stem cell factor (SCF). pp71-induced SCF did not stimulate proliferation of NPCs in an autocrine manner, but rather activated its cognate receptor, c-kit, on human umbilical vein endothelial cells (HUVEC) and induced capillary tube formation in cell culture angiogenesis assays. Neutralizing antibodies to SCF blocked the pp71-induced HUVEC tube formation, demonstrating specificity of this proangiogenic effect. Furthermore, conditioned medium from pp71-transduced NPCs enhanced migration of endothelial cells and hematopoietic progenitor cells in a transwell migration assay. These results indicate that pp71 expression in glioma likely promotes angiogenesis, a pathological hallmark of this malignancy, thus enhancing the growth and aggressiveness of GBM. Human cytomegalovirus (HCMV) infection and expression occurs in a high percentage of human glioblastoma multiforme (GBM) tumors; however, the role of the virus in the pathogenesis of this uniformly fatal cancer has yet to be characterized. We sought to determine whether US28, an HCMV encoded G-protein like coupled receptor homologue, is expressed in human GBMs and how it may promote oncogenic signaling in glioma and in neural precursor cells (NPCs)-the likely cells of origin for glioma. Using immunohistochemical and RT-PCR approaches, we detected expression of various strains of HCMV US28 in a majority of human GBM tissues and primary cultures examined. We found that HCMV infection or overexpression of US28 in NPCs and primary GBM cells promoted secretion of biologically active vascular endothelial growth factor (VEGF) and activation of multiple cellular kinases that promote glioma growth and invasion, including phosphor-STAT3 and eNOS. US28 overexpression increased primary GBM cell invasion in Matrigel assays, which was further enhanced by stimulation with RANTES/CCL5, a US28 ligand upregulated by HCMV infection of NPCs. High levels of CCL5 are associated with a mesenchymal phenotype and poor patient outcome in GBMs, suggesting that the US28-CCL5 paracrine signaling may contribute to glioma progression. Finally, we demonstrated that US28 co-localized with markers of angiogenesis and inflammation (VEGF, p-STAT3, COX2, e-NOS) in human GBMs in situ. Taken together, our findings indicate that US28 induces a proinflammatory and angiogenic microenvironment, which promotes the pathogenesis of HCMV positive gliomas. Glioblastoma (GB) is a highly invasive and lethal brain tumor because of its universal recurrence. Here we focused on of the role of electroneutral Na + -K + -Cl-cotransporter-1 (NKCC1) in the invasion of human primary glioma cells in vitro and glioma stem cells in vivo. NKCC1 expression levels were significantly higher in GB and anaplastic astrocytoma tissues than in grade II glioma and normal cortex tissues (p , 0.001). Pharmacological inhibition and decreased expression of NKCC1 led to decreased migration and invasion in vitro (p , 0.05) and in vivo (p , 0.005). NKCC1 knockout cells also showed significantly larger focal adhesions and generation of approximately 40% lower contractile moments than did control shRNA cells (p , 0.05 and p , 0.01, respectively). Also, the inhibition of K + -Cl-cotransport (KCC), a Cl-extruding mechanism and the counterpart of NKCC1, led to a more migratory behavior of primary human glioma cells when compared with control cells (p , 0.05). Furthermore, our results showed that epidermal growth factor (EGF), which promotes migration of glioma cells, increased the phosphorylation of NKCC1 through the novel family of WNK kinases, which regulate NKCC and KCC transporters reciprocally. This suggests that the activity of the WNK kinases may determine the migratory ability of glioma cells. Our results provide evidence that primary human GB cells require ion transport and expression of NKCC1 for efficient migration. The mechanisms that confer to GB cells this invasive behavior and their regulatory system have not been fully elucidated. Our results indicate that NKCC1 modulates migration of GB cells by two different mechanisms: regulation of focal adhesion dynamics and cell contractility and cell volume regulation (through ion transport). Their roles in GB cell invasion may allow NKCC1 and its regulation by WNK3 to serve as therapeutic targets to decrease GB cell invasion. Because of the ubiquitous expression of NKCC1 and the WNK kinases in mammalian tissues, our results can be extrapolated to other highly invasive neoplasias. INTRODUCTION: Glioblastoma, the most common and aggressive primary brain tumor in human adults, has many different strategies leading to an efficient immune escape and resulting in an impaired recognition as well as ineffective attack of tumor cells by the immune system. Furthermore, extensive and diffuse invasion of tumor cells limit the efficacy of local treatment approaches such as surgical resection and radiotherapy. 4IgB7H3, a member of the B7-family of costimulatory proteins, has been shown to convey immunosuppression and enforced invasiveness in a variety of tumors associated with poor prognosis. Here we examine the role of 4IgB7H3 in glioblastoma. EXPERIMENTAL DESIGN AND RESULTS: 4IgB7H3 was expressed in glioma cell lines, glioma initiating cells, and human glioma tissue samples. 4IgB7H3 expression by tumor and endothelial cells correlated positively with the malignancy grade and with poor survival. A soluble form of 4IgB7H3 at 93 kDa lacking the intracellular and the transmembrane domain has been identified in the supernatant of glioma cells. Both cell-bound and soluble 4IgB7H3 are functional and suppress natural killer cell -mediated tumor cell lysis. Gene silencing of 4IgB7H3 in the glioma cell line LN-229 and a glioma initiating cell culture reduces the proinvasive phenotype in vitro and, more importantly, in an in vivo orthotopic xenograft tumor model. CONCLUSIONS: The immunosuppressive and proinvasive functions of 4IgB7H3 may allow it to serve as a therapeutic target in the treatment of glioblastoma. We present a novel 3D culture system to create macroscopic tumor aggregates and present initial findings characterizing these tumor masses. We describe the formation of a substantial ECM, upregulation of angiogenic pathways, and exhibition of vessel-like qualities by tumor cells (so-called vasculogenic mimicry). METHODS: The Rotary Cell Culture System (RCCS) was used to cultivate 1-cm diameter aggregates of high grade glioma and medulloblastoma cell lines. RNA was extracted from both 3D and monolayer cultures in addition to the primary tumor from which one of the high grade glioma lines was derived. Expression of 84 angiogenesis and 84 ECM related genes was assessed by RT-PCR. Aggregates were formalin fixed and paraffin embedded, and immunohistochemistry was performed against known vessel-related antigens (e.g. CD105), ECM components, and components of angiogenic pathways (e.g. VEGF). RESULTS: Immunohistochemistry demonstrates that the tumor aggregates possess a complex structure with distinct proliferating, senescent, and necrotic regions, replicating the primary tumor; the aggregates also have a similar cell population density to the primary tumor. Tubular structures within the aggregates, with sporadic expression of antigens such as CD105, represent vasculogenic mimicry by tumor cells. Many key angiogenic and ECM genes are greatly upregulated in 3D compared with 2D culture (p , 0.05). Scanning electron microscopy confirms extensive ECM deposition in the aggregates. U133plus2 gene expression analysis also identified multiple proangiogenic genes upregulated in 3D culture. Cellular capability to form vascular networks has been assessed in a Matrigel assay. The effects of inhibition of key angiogenic pathways have been examined. CONCLUSIONS: Tumor cell lines significantly upregulate many key angiogenic and ECM genes as a consequence of 3D culture, recapitulating vasculogenic mimicry. Our findings contribute to our understanding of angiogenic processes in pediatric brain tumors and the possible mechanisms of resistance to current antiangiogenic therapies. The 3D culture system permits modeling of vasculogenic processes in a pathophysiologically relevant context.
AI-04. HUMAN CYTOMEGALOVIRUS-ENCODED GPCR US28 PROMOTES THE INVASION AND ANGIOGENESIS OF GLIOBLASTOMAS

AI-08. RADIOGRAPHIC PATTERNS OF RECURRENCE WITH PATHOLOGIC CORRELATION IN PATIENTS WITH MALIGNANT GLIOMAS TREATED WITH BEVACIZUMAB (BEV)
Thomas J. Kaley, Jason Huse, Sasan Karimi, Marc Rosenblum, Antonio Omuro, and Lisa M. DeAngelis; Memorial Sloan-Kettering Cancer Center, New York, NY BACKGROUND: Recent reports have described varying radiographic patterns of recurrence of malignant gliomas (MG) after treatment with bevacizumab, including both enhancing and nonenhancing progression, with MR-perfusion (MR-P) and diffusion weighted imaging (DWI) results. However, little data exist from pathologic review of tumor specimens after progression on bevacizumab. METHODS: We retrospectively reviewed all bevacizumab-treated MG patients at MSKCC and analyzed those who had undergone either re-operation for tumor progression or autopsy after receiving bevacizumab. MRIs were reviewed to determine recurrence pattern (local enhancing, distant enhancing, or non-enhancing tumor), and DWI, MR-P, and FDG-PET scans were reviewed when available. Post-bevacizumab tumor specimens were examined both histologically and for genome-wide gene expression for molecular subclassification and were compared with prebevacizumab specimens when available. RESULTS: 32 MG patients (26 GBM, 3 AA, 3 AO) were identified who underwent either surgical resection (n ¼ 26) or autopsy (n ¼ 6) after bevacizumab treatment. PATIENTS: the median age was 56 yrs (18-81); 25 were male; the median KPS was 90% (70-100); 10 were treated with upfront bevacizumab, 22 at recurrence; 13 received bevacizumab alone, 19 received bevacizumab with chemotherapy (13 TMZ, 5 CPT-11, 1 CCNU). On MRI, 23 patients had local enhancing recurrence, 1 had distant enhancing recurrence, 7 had nonenhancing recurrence, and 1 had diffuse leptomeningeal recurrence. Histology demonstrated tumor recurrence (25), mixed tumor/necrosis (5), and nearly all necrosis (2; both local enhancing recurrence). 5 patients had restricted diffusion (3 mixed, 2 nearly all necrosis). MR-P scans were reviewed of 12 patients: 8 hyperperfusion (7 tumor, 1 mixed) and 4 hypoperfusion (2 mixed, 2 necrosis). FDG-PET scans were reviewed of 4 patients: 1 hypermetabolic (mixed) and 3 hypometabolic (2 tumor, 1 mixed). CONCLUSIONS: Standard MRI reveals multiple recurrence patterns. Tumor was found in 94% of cases, and necrosis was seen. Further histologic review may help distinguish between necrosis and tumor. Restricted diffusion correlated with necrosis more than tumor. Gene expression profiling and molecular subclassification are being performed and will be presented at the meeting.
Determining the mechanism of treatment failure of anti-VEGF therapies for malignant glioma patients would provide insight into either potential combination approaches or salvage therapies to overcome therapeutic resistance. In multiple established murine model systems of intracerebral glioma, animals were treated with either bevacizumab or cediranib, and upon treatment failure, intratumoral expression levels of the phosphorylated-signal transducer and activator of transcription 3 (p-STAT3) were measured and infiltrative patterns evaluated. Tumor expression of p-STAT3 was compared in patients with recurrent glioblastoma who were treated with conventional chemotherapy or bevacizumab upon progression. Although both bevacizumab and cediranib extended median survival time in murine model systems of established intracerebral glioma, bevacizumab markedly increased the mean percentage of p-STAT3 -expressing tumor cells to 24.6 + 6.4% (P ¼ 0.0011) and cediranib increased this to 16.2 + 1.8% (P ¼ 0.0125) relative to 9.0 + 4.4% seen in controls. The pattern of treatment failure was notable for p-STAT3 expressing cells diffusely spreading to the contralateral hemisphere. A similar trend was obtained in patients with recurrent glioblastoma who were treated with bevacizumab and had a mean of 36.5 + 8.6% (n ¼ 7) p-STAT3 -expressing cells compared with a recurrent glioblastoma cohort that had never received any type of anti-VEGF therapy and had a mean of 16.3. + 1.2% (n ¼ 4; P ¼ 0.05) p-STAT3 -expressing cells. Furthermore, in a separate cohort of glioblastoma patients, the majority demonstrated upregulation of p-STAT3 in the peripheral blood mononuclear cells within 24 hours after initial bevacizumab administration. Cumulatively, these data suggest that a prominent mechanism of failure of anti-VEGF therapy in malignant glioma patients involves upregulation of the STAT3 pathway and may ultimately justify the use of STAT3 inhibitors concurrently with anti-VEGF therapies or as a salvage therapy.
AI-10. NOSCAPINE IS EFFECTIVE FOR TREATMENT OF TMZ-RESISTANT GLIOMAS
Niyati Jhaveri, Heeyeon Cho, Shering Torres, Weijun Wang, Axel Schonthal, Nicos Petasis, Stan G. Louie, Florence Hofman, and Thomas C. Chen; University of Southern California, Los Angeles, CA Glioblastoma multiforme (GBM) is the most common and malignant of all gliomas, with a 5-year overall survival rate of less than 3.3%. Temozolomide (TMZ) is the current standard of care for GBM; however, these tumors are highly recurrent, and the development of TMZ resistance is a major problem. Therefore, therapies that target TMZ-resistant tumors are sorely needed. To approach this problem, we developed human TMZ-resistant glioma cell lines. We investigated the effects of the antitussive (cough suppressant) alkaloid noscapine, a well tolerated agent shown to have antitumor activity and to cross the blood-brain barrier, on these TMZ-resistant glioma cells. In in vivo studies using the intracranial murine model of TMZ-resistant human glioma cells, we demonstrated that orally administered noscapine significantly prolonged the survival of these animals in the absence of any observable toxic effects. To understand the mechanism underlying this antitumor outcome, we studied the effects of noscapine on the proliferation, migration, and invasion of TMZ-resistant glioma cells in vitro. At nontoxic concentrations, noscapine decreased migration and invasion, and at higher concentrations it caused significant reduction of proliferation and survival of these highly drug-resistant tumor cells. Noscapine significantly reduced proliferation as determined by the colony forming assay. The mechanism of cytotoxicity is currently under investigation. In summary, our studies demonstrate that noscapine may be a potent therapeutic option for the treatment of patients with TMZ-resistant GBM.
AI-11. A NOVEL THROMBOSPONDIN-1 MIMETIC PEPTIDE, ABT-898, DECREASES ANGIOGENESIS IN A MOUSE MODEL
OF GLIOBLASTOMA MULTIFORME Ryosuke Yamada; The Ohio State University Medical Center, Columbus, OH
The prognosis for patients with glioblastoma multiforme (GBM) still appears bleak despite medical advances in the treatment of other malignant tumors in the past decades. With optimal therapy of surgical resection, radiation therapy, and chemotherapy, the approximate median survival is merely 12 months. However, a recent discovery that the microvascular niche of such tumors plays a critical role in their maintenance has led to development of antiangiogenenic therapies that target it. To evaluate the in vitro effect of ABT-898, a TSP-mimetic, antiangiogenic peptide, we used human brain microvascular endothelial cells (HBMEC) to model its in vivo effects on human brain microvasculature. Furthermore, to assess ABT-898's clinical applicability, an orthotopic xenograft mouse model was established using human-derived GBM cells lines, and its therapeutic effect was evaluated in vivo. We found that ABT-898 induced apoptosis in HBMEC as evidenced by increased fraction of annexin-V -positive cells on flow cytometry. Similarly, a significant level of apoptosis was also observed on TUNEL assay at a concentration as low as 100 nM. Systemic treatment of BTSC-derived immunodeficient mouse tumors with ABT-898 significantly reduced the tumor burden compared with that of a vehicle, which was used as a control. ABT-898's antiangiogeneic property in vivo was further characterized using dynamic contrast enhanced-magnetic resonance imaging. In addition, treatment with ABT-898 allowed increased median survival in the xenograft models compared with control mice. These observations suggest that ABT-898 is a plausible candidate for use in the future treatment of GBM. Glioblastoma multiforme (GBM) is the most common, aggressive, and lethal form of glioma in adults. The identification of proteins critical to GBM function has become important to provide a better treatment for patients with GBM. In recent years, our group identified IQ-domain GTPase activating protein (IQGAP1), a scaffolding protein. IQGAP1 protein expression is intensified in the pseudopalisading cells surrounding the necrotic foci and is implicated as playing a key role in migration in other cancers. We reported that over 80% of GBMs were IQGAP1-positive and that this expression was associated with poor survival outcome. IQGAP1, a target molecule of Cdc42 and Rac1 small GTPases, plays a role in cellular motility and morphogenesis by interacting directly with cytoskeletal, cell adhesion, and signal transduction proteins. IQGAP1 also interacts with VEGFR2 to promote endothelial cell migration and ultimately stimulates angiogenesis Functional studies addressing IQGAP1 in GBM are limited, as are studies of its role in the interaction between GBM and endothelial cells. In this study, we ascertained the precise role of IQGAP1 in GBM migration. The tumorigenic human GBM cell line U251 was chosen as the model, as IQGAP1 protein and mRNA expression were highly upregulated. Inhibiting IQGAP1 with siRNA attenuated cell migration. However, no effect was seen in the cell proliferation. We explored the precise role of IQGAP1 in GBM cell migration using a novel technique called photolithography. mCherry-tagged U251 and GFP-tagged endothelial cells (HMEC) were aligned in the 3D grooves of microchannels, and the interaction between the two cells was observed. The effects of the inhibition of IQGAP1 on U251 and HMEC interactions were also determined. This study confirmed the role of IQGAP1 in GBM migration. Combinations of drugs targeting IQGAP1 with traditional cytotoxic drugs present a potential therapeutic option for GBM for future investigation. Promotion of tumor cell motility and invasiveness is known to be an essential mode of acquired resistance to radiotherapy in various cancer types, including glioblastoma. This process resembles evasive resistance, which likely underlies progressive disease and complicates further treatment. Hence, a logical advancement of radiotherapy would be to identify suitable complementary strategies, ideally targeting cell motility. Here we report that the combination of focal radiotherapy and the inhibition of the serine/threonine kinase mammalian target of rapamycin (mTOR) using clinically relevant concentrations of temsirolimus (CCI-779) prolongs survival in a syngeneic mouse glioma model through additive cytostatic effects. CCI-779 exerted marked antiinvasive effects irrespective of the phosphatase and tensin homolog (PTEN) status and counteracted the proinvasive effect of sublethal irradiation in vitro. In comparative microarray-based transcriptome analyses, we identified regulator of G protein signaling 4 (RGS4) as a novel target of mTOR inhibition and a key driver of glioblastoma invasiveness sensitive to the antiinvasive properties of CCI-779. Importantly, suppression of RGS4-dependent glioma cell invasion was signaled through both mTOR complexes-mTORC1 and mTORC2-in a concentrationdependent manner, indicating that high doses of CCI-779 may overcome protein kinase B (AKT/PKB)-mediated tumor cell resistance associated with the sole inhibition of mTORC1. In conclusion, our findings show
AI-12. IQGAP1 PLAYS
AI-13. OPTIMIZATION OF GLIOMA TREATMENT THROUGH SUPPRESSION OF PROINVASIVE RGS4 BY MTOR INHIBITION
that combined radiotherapy and mTOR inhibition is a promising therapeutic option in upfront glioblastoma therapy. The invasion of glioblastoma cells into the brain blurs the border between tumor mass and surrounding parenchyma, thereby complicating complete surgical resection. Rho GTPases play a major role in the regulation of tumor cell invasion. These proteins are activated via interaction with guanine nucleotide exchange factors (GEFs). In this study, we focused on PDZ-RhoGEF (a member of the regulators of G-protein signaling (RGS) GEF family). It has been shown that invading glioblastoma cells need contractile force to squeeze their nucleus through the narrow spaces that are characteristic of the brain parenchyma (Beadle et al. Mol. Biol. Cell (2008) 19: 3357) . We found that depletion of PDZ-RhoGEF in U87 and SNB18 glioblastoma cells strongly inhibits cell migration across a small (3 mm) pore size filter, a process that necessitates nuclear squeezing. PDZ-RhoGEF depletion also inhibits cell migration across a larger (8 mm) pore size filter, albeit to a lesser extent than in the squeezing assay. In addition, PDZ-RhoGEF depletion strongly inhibits glioblastoma cell invasion into ex vivo brain slices. Thus, PDZ-RhoGEF is necessary for glioblastoma cell migration, nuclear squeezing, and invasion. Interestingly, PDZ-RhoGEF-depleted cells are elongated and display a disorganized leading edge. We also observed that depletion of PDZ-RhoGEF strongly inhibits the survival of glioblastoma cells after ionizing radiation, although it does not significantly affect cell proliferation. Taken together, our findings suggest that PDZ-RhoGEF is a potential target for glioblastoma therapy.
AI-15. CIRCULATING ENDOTHELIAL CELLS IN THE PERIPHERAL BLOOD OF PATIENTS WITH GLIOBLASTOMA
AT THE TIME OF PROGRESSION AFTER TREATMENT WITH RESECTION AND ADJUVANT CHEMORADIOTHERAPY Abigail L. Stockham, Ernest Borden, and David Peereboom; Cleveland Clinic, Cleveland, OH INTRODUCTION: Circulating endothelial cells (CECs) have been identified as a potential biomarker of various vascular disorders as well as certain malignancies. CECs in patients with glioblastoma multiforme (GBM) have never been described. We sought to assess the feasibility of identifying and quantifying CECs in patients with GBM. METHODS: Eligible patients had GBM with radiographic progression after maximal surgery followed by standard radiation therapy and concurrent daily temozolomide followed by monthly temozolomide daily x 5, KPS . 60, and no prior bevacizumab treatment. Descriptive parameters were obtained for each patient including demographics, disease and treatment characteristics, and patient outcomes. Blood tests were obtained at the time of clinical progression. CECs were quantified by immunomagnetic enrichment using the Veridex system (Veridex LLC, Raritan, NJ) and were compared with previously identified normal CEC values of , 40 CEC/4 mL blood. RESULTS: Fourteen patients were included in this study, from whom 11 samples were evaluable. Three samples hemolyzed prior to analysis. Eight patients received an additional systemic agent concurrent with high dose temozolomide. The mean time to progression was 9.2 months (range, 1-32 months). For the eleven patients whose samples were evaluable, CECs were observed in all samples, with a mean of 50 CEC/4 mL blood (range, 8-185 CEC/4 mL blood). Six patients had elevated numbers of CECs, with a mean of 61 CEC/4 mL blood (range, 40 -185 CEC/4 mL blood). CONCLUSION: CECs are present in a high proportion of patients with glioblastoma at the time of progression. Future studies with larger patient numbers will be needed to correlate this potential biomarker with clinical outcomes. A study is planned to evaluate the effects of bevacizumab on CECs.
AI-16. EGF CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 1 SUPPRESSES GLIOBLASTOMA CELL GROWTH IN VIVO
Yuanjie Hu, Abhishek Chaturbedi, Mark Hamamura, E Mark, and Yi-Hong Zhou; University of California, Irvine, Irvine, CA We have identified that the gene encoding EGF containing fibulin-like extracellular matrix protein 1 (EFEMP1) mediates the tumor suppression function of transcription factor PAX6 in controlling malignant glioma cell growth in vivo. Overexpression of EFEMP1eliminated tumor development while the converse was true with knock-down endogenous EFEMP1. Human recombinant EFEMP1 protein has been reported to suppress angiogenesis in vivo. We therefore undertook a study of exogenous EFEMP1 protein application to see whether it would be capable of suppressing glioblastoma multiforme (GBM) cell growth in vivo. Human recombinant EFEMP1 or control vehicle was either mixed with GBM-derived cell lines and primary GBM cultures prior to subcutaneous and intracranial implantations or injected circumferentially around established subcutaneous xenografts. For the subcutaneous experiment, xenograft volumes were measured on a scheduled basis and tumors were weighed at the end of the experiment. For intracranial experiment, mice survival data following implantation were subjected to statistical analyses, and magnetic resonance imaging (MRI) was used for temporal comparison of intracranial tumor development. Results from both the subcutaneous and intracranial experiments showed that direct administrations of EFEMP1 protein significantly suppressed malignant glioma cell tumorigenicity, with smaller subcutaneous tumors and longer mouse survival after intracranial implantation of glioma cell line U251HF. T2-weighted MRI revealed smaller intracranial tumors in mice implanted with U251HF cells plus EFEMP1 compared with U251HF cells plus vehicle. Although no significant improvement in mouse survival was observed after intracranial implantation of a GBM primary cells with EFEMP1, contrast-enhanced T1-weighted MRI revealed central necrosis in the intracranial xenograft from vehicle treatment, while homogenous enhancement without necrosis was seen in the intracranial xenograft from EFEMP1 treatment. Overall data revealed EFEMP1's functioning location in the tumor extracellular compartment. Thus, exogenous tumor parenchymal application of EFEMP1-derived peptides has the potential to be developed into a new therapeutic agent and strategy for patients with malignant glioma. Glioblastomas (GBMs) are hyperglycolitic in order to adapt to the hypoxic stress caused by their fast growth. We have found that 2-deoxyglucose (2-DG), an inhibitor of glucose metabolism, induces differentiation of GBM stem-like cells toward a neuronal commitment as well as early apoptotic cell death in the presence of 20% O 2 but not under hypoxic conditions (2% O 2 ). In the present study, we examined the role of glycolysis and of 2-DG in the proliferation, invasion, and speed of motility of GBMs. We found that 2-DG significantly decreased cell proliferation, speed, and invasion capacity (p , 0.05), as evaluated by EdU incorporation, migration assay on nanopattern surfaces, and Transwell invasion assays, respectively. Moreover, when GBM cells were allowed to recover from 2-DG exposure by re-introducing glucose to their media they exhibited a more aggressive phenotype than that of untreated cells. We hypothesized glucose-6-phosphatase (G6Pase), an enzyme involved in glucose metabolism, plays a pivotal role in the aggressive behavior of GBM cells observed after recovery from 2-DG treatment. G6Pase exhibits a 2-fold increase in mRNA expression when cells are treated with 2-DG; such increase doubles when cells are allowed to recover with glucose (p , 0.05). To test the role of G6Pase in the observed effects, we used chlorogenic acid (CHL), an inhibitor of G6Pase activity. CHL inhibited the aggressive behavior of GBM cells in the recovery group by decreasing cell invasion compared with 2-DG-recovered cells with no CHL (p , 0.05). These encouraging results suggest a role of G6Pase in promoting a mechanism of cell survival from the glycolytic inhibition induced by 2-DG. Tumor recurrence after current treatments is a main cause of death in GBM patients and is the focus of multiple research endeavors. Our results demonstrate that GBM cells' ability to adapt to adverse conditions relies, at least in part, on metabolic changes. Diffuse intrinsic pontine glioma (DIPG) accounts for a significant fraction of pediatric brain tumors, but is rarely subjected to biopsy or autopsy examination. We present a series of five postmortem brain examinations of children with DIPG. Four of the patients died from progressive disease after initial therapy followed by tumor recurrence; one child died without therapy and within three months of initial diagnosis. Brains were systematically evaluated for evidence of tumor dissemination. Pontine tumors were all classified as WHO grade II-IV astrocytic neoplasms, and all exhibited nestin immunoreactivity to varying degrees. Higher nestin immunoreactivity correlated with higher tumor grade and more extensive distant invasion. In all five subjects, extension of tumor to the midbrain and cerebellum was observed. In all four cases of recurrent DIPG, tumor extended supratentorially into the thalamus. In two cases, tumor was evident on the frontal lobes as far rostral as the frontal horns of the lateral ventricles. Strikingly, tumor infiltration of supratentorial brain occurred specifically in the subventricular zone of the third and lateral ventricles. Tumor invasion restricted to this neurogenic niche supports observations by us and others that DIPG tumor cells are phenotypically and molecularly similar to normal neural stem cells and appear to depend on many of the same trophic signals.
AI-17. METABOLIC ADAPTATION OF HUMAN GLIOBLASTOMA CELLS TO GLYCOLYSIS INHIBITION: HOW TO MAINTAIN A LONG-TERM BENEFICIAL EFFECT
AI-18. SUPRATENTORIAL SPREAD IN THE NEUROGENIC NICHE OF DIFFUSE INTRINSIC PONTINE GLIOMA
AI-19. BRAIN TUMOR STEM CELL 4 (BTSC4) IS EXPRESSED ON GLIOBLASTOMA PROGENITOR CELLS AND INVOLVED IN THE REGULATION OF TUMOR CELL INVASION
Noriyuki Kijima, Naoki Hosen, Naoki Kagawa, Naoya Hashimoto, Yasunori Fujimoto, Manabu Kinoshita, Haruo Sugiyama, and Toshiki Yoshimine; Osaka University Graduate School of Medicine, Suita, Japan Prognosis of glioblastoma multiforme (GBM) patients remains poor. To improve this prognosis, it is important to identify GBM progenitor cells and target them. In this study, we found that BTSC4 (announced by anonymity because we are applying for a patent) was highly expressed in the CD133 + GBM progenitor cell populations. In the CD133
+ GBM cell population, BTSC4 + cells were highly enriched with tumor-sphere-initiating cells in vitro. We also found that the frequencies of BTSC4-positive cells on tumor specimens were significantly correlated with the gliomas' WHO histological grade and the prognosis of GBM patients. The function of BTSC4 in GBM was also examined. Transfection of BTSC4 siRNA to U87MG cells significantly increased cell invasion in a Matrigel invasion assay without affecting cell proliferation. The known BTSC4 ligand was also expressed in all GBM samples, and in vitro invasion of U87MG GBM cells was significantly enhanced by administrating purified BTSC4 ligand. Furthermore, overexpression of BTSC4 ligand in U87MG GBM cells promoted tumor progression in intracranial transplants to immune-deficient mice. In summary, BTSC4 can be a new GBM progenitor marker and also a prognostic marker, and BTSC4 is involved in the regulation of GBM invasion. In addition, BTSC4 ligand-which is also expressed in GBM cells-promotes GBM invasion, suggesting that BTSC4 ligand is a potent therapeutic target against GBM. Gliomas are notoriously difficult to treat, resulting in patients still suffering a very bad prognosis. A major problem of these tumors is the presence of extensive diffuse infiltrative growth in the normal brain parenchyma, which results in a shielding of tumor cells from therapeutic compounds by the blood-brain barrier. The occurrence of areas of profound angiogenesis in glioblastomas, a hallmark of these tumors, has resulted in the application of antiangiogenic compounds for treatment of these tumors. Treatment of glioblastomas with the anti-VEGF antibody bevacizumab in combination with irinotecan results in impressive radiological responses, although these seem not to be accompanied by prolonged survival. It is gradually becoming evident that the radiological pseudoresponse has its basis in an antiangiogenic agent-induced restoration of the blood-brain barrier in angiogenic areas, leading to a loss of contrast enhancement in MRI scans. Importantly, the diffuse infiltrative tumor areas can progress behind an intact blood-brain barrier. This phenomenon urges the need for new imaging modalities to evaluate glioma response to such therapies. In this study, we analyzed the use of magnetic resonance spectroscopy (MRS) in orthotopic glioma xenografts treated with several antiangiogenic agents.
AI-20. EVALUATION OF IN VIVO MAGNETIC RESONANCE SPECTROSCOPY AS A TOOL TO VISUALIZE DIFFUSE INFILTRATIVE GLIOMAS AFTER ANTIANGIOGENIC THERAPY
MRS is a noninvasive imaging method that provides functional information regarding cell membrane metabolism, neuronal integrity, and energy metabolism. Using a 7T Bruker system, MR spectra and Gd-DTPA-enhanced T1-weighted MR images were obtained from animals with tumors either untreated or treated with antiangiogenic compounds. Results were correlated to immunohistochemical stainings of postmortem brains. Our data show that whereas contrast enhancement is lost in response to antiangiogenic therapy, the choline-N acetyl aspartate ratio as determined by MRS is a reliable marker for the persistence of tumor. MRS seems to be a valuable tool for monitoring gliomas, especially after treatment with antiangiogenic agents. Cancer patients show endothelial alterations documented by abnormal circulating endothelial cell (CEC) and progenitor (CEP) levels and by specific antigenic profiles of vessel-lining ECs, including CD109 expression (Seaman et al., 2007) . The role of CECs and CEPs in high grade gliomas (HGG) has not been investigated previously. Bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, has significant activity in HGG patients, and we investigated the role of CECs and CEPs in this setting. Forty-seven patients with recurrent HGG (38 glioblastomas, GB; 9 anaplastic astrocytomas) were treated biweekly with bevacizumab (10 mg/kg) and irinotecan (125 or 340 mg/m 2 , depending on the EIAEDs used). The numbers and viability of CECs (Syto + CD45-CD31 + /P1h12+) and CEPs (Syto + CD45-CD31 + /CD133+) were assessed in healthy controls (n ¼ 37) and patients before treatment and every 8 weeks by flow cytometry. CD109, VEGFR2, and CD140b-expressing endothelial subpopulation were also assessed. Brain MRI was performed at baseline and every 8 weeks and, progression was defined by RANO criteria. Median progression-free survival (PFS) and overall survival (OS) were 6 and 10 months, respectively. For GB, 6mos-PFS was 47% and 6mos-OS 68%. The baseline fraction of CD109+ CECs was higher in HGG patients than in healthy controls (91.5 + 78. (BAI1) is a putative G protein-coupled receptor that has potent antiangiogenic and antitumorigenic properties and is mutated in certain cancers. BAI1 is expressed in normal human brain but it is silenced in glioblastoma multiforme (GBM). In this study, we show that this silencing event is mediated by upregulation of methyl-CpG-binding domain protein 2 (MBD2), a key mediator of epigenetic gene regulation, which hypermethylates the BAI1 gene promoter. In glioma cells, treatment with 5-aza-2'-deoxycytidine (5-Aza-dC), which elicits DNA demethylation, was sufficient to reactivate BAI1 expression. Chromatin immunoprecipitation (ChIP) showed that MBD2 was enriched at the promoter of silenced BAI1 in glioma cells and that MBD2 binding was released by 5-Aza-dC treatment. RNAi-mediated knockdown of MBD2 led to reactivation of BAI1 gene expression and restoration of BAI1 functional activity, as indicated by increased anti-angiogenic activity in vitro and in vivo. Taken together, our results suggest that MBD2 overexpression during glioma progression may drive pathobiology by suppressing the antiangiogenic activity of a key tumor suppressor. These findings have therapeutic implications because inhibiting MBD2 could offer a strategy to reactivate BAI1 and suppress glioma pathobiology. Brain Angiogenesis Inhibitor 1 (BAI1), an orphan GPCR-type seven transmembrane receptor, was recently found mutated or silenced in multiple human cancers and can interfere with tumor growth when overexpressed. Yet little is known about the molecular mechanisms through which this novel tumor suppressor exerts its anticancer effects. Here, we demonstrate that the N-terminus of BAI1 is cleaved extracellularly to generate a truncated receptor and a 40-kDa fragment that dramatically inhibits angiogenesis. We demonstrate that this novel proteolytic processing event depends on a two-step cascade of protease of activation: proprotein convertases, primarily furin, activate latent matrix metalloproteinase 14, which then directly cleaves BAI1 to release the bioactive fragment. These findings significantly augment our knowledge of BAI1 by showing a novel posttranslational mechanism regulating BAI1 activity through cancer-associated proteases. Our findings have important implications for BAI1 function and regulation and present novel opportunities for therapy of cancer and other vascular diseases. The role of bone marrow-derived cells (BMDCs) in tumor neovascularization in glioblastoma multiforme (GBM) remains controversial. Our study focuses on establishing the spatiotemporal contribution of BMDC to GBM neovascularization based on tumor growth stage, regional differences, and response to ionizing radiation (IR). METHODS: Our experimental strategy is to use an intracranial window coupled with 2-photon laser microscopy for high-resolution in vivo longitudinal imaging of single-cell BMDC in normal brain and brain tumor vasculature. We use chimeric mice with reconstituted GFP + bone marrow (BM) to create GBM xenografts (mCherry + U87 or U251) in addition to chimeric transgenic models of spontaneous GBM with GFP + BM. Correlative histological analysis complements 2PLM results. Laser-capture microdissection (LCM) is used to isolate vessels from the center versus the periphery of the tumor, and we perform quantitative real-time PCR for differential gene expression profiling. RESULTS: We demonstrate a tumor growth stage dependent integration of BMDC into tumor vasculature. At early stages of tumor growth (,1 wk) there is 90% integration of BMDCs into vasculature, but at later stages (.3 wks) only 10% of vessels show BMDC integration. There is a distinct regional difference in BMDC integration pattern, with peripheral vessels demonstrating 90% BMDC integration while the central vessels show none. LCM and IHC confirm differences in the genetic expression profile of the periphery compared with the central vasculature. BMDCs integrating into vasculature are CD133 + , and in the periphery BMDCs differentiate to form inflammatory cells, endothelial cells, and smooth muscle cells. Following IR, the distinct regional difference in BMDC integration is lost, with both center and periphery demonstrating a similar extent of BMDC integration. CONCLUSION: Our novel findings confirm distinct tumor growth stage-dependent and highly regionally dependent contribution of BMDCs to tumor neovascularization, suggesting that distinct mechanisms of vascularization are at play in GBM progression. IR obliterates this distinct regionally dependent BMDC contribution, which has significant therapeutic implications.
AI-21. RELEVANCE OF CD1091 CIRCULATING ENDOTHELIAL CELLS IN RECURRENT HIGH GRADE GLIOMAS TREATED WITH BEVACIZUMAB AND IRINOTECAN
AI-24. THE ROLE OF BONE MARROW -DERIVED CELLS IN TUMOR STAGE -DEPENDANT NEOVASCULARIZATION
AI-25. EX VIVO EVALUATION OF TUMOR CELL MIGRATORY CHARACTERISTICS IN A HUMAN GLIOBLASTOMA SLICE CULTURE MODEL
Jonathon J. Parker, Kalen Dionne, Rada Massarwa, Marci Klaassen, Lee Niswander, B.K. Kleinschmidt-DeMasters, and Allen Waziri; University of Colorado School of Medicine, Aurora, CO Brain invasion is a hallmark of glioblastoma (GBM) and a barrier to curative treatment. As such, models allowing for physiologically relevant interpretation of tumor cell migratory characteristics are critical for ongoing study. We have recently developed a method for time-lapse imaging of human tumor cell migration in an ex vivo GBM organotypic slice model generated from freshly resected tumor specimens. Infection of slices with a ZsGreen-expressing retrovirus and time-lapse laser confocal imaging (10-20 h) has resulted in the identification of several distinctly labeled populations via morphology and migratory characteristics.
Stationary cells or those with highly directional migration had the predicted appearance of tumor cells, represented by long, polarized, and dynamic processes and canonical saltatory movement of the cell body. Also observed was a smaller subset of cells with the morphological features of microglia that migrated with greater speed but less directionality. Migratory paths of tumor cells were manually tracked, and the resulting data were postprocessed to determine the mean migratory speed (total distance over time) and directionality (net path length divided by total path length). Using this system, we noted significant differences in the migratory characteristics of tumor cells from different patients. Average migration speeds varied from 2.1 to 8.5 mm/h, and greater speeds were associated with more highly directional movement (i.e. directionality ratios closer to 1.0). This study provides the first visualization of glioma cells migrating in living human brain tissue. Ongoing studies are attempting to correlate tumor cell migration data and patient-matched biomathematical metrics of invasion and proliferation obtained from MRI analysis. We predict that this system will provide new insight into the dynamics of GBM growth and dispersion. Furthermore, slice cultures generated from surgical specimens could provide a patient-specific approach to study the effects of therapeutics on the migration, proliferation, and survival of glioma cells in living brain tissue. While meningiomas are considered benign tumors, a subset of these tumors invades bone, causing hyperostosis and invasion of adjacent neural and soft tissues. Bone-invading meningiomas represent a considerable clinical challenge because complete surgical resection is often not possible, resulting in higher recurrence rates and repeat surgery. The goal of this study is to identify differential gene and protein expression profiles of bone-invading and noninvading meningiomas; the ultimate goal is to establish potential novel therapeutic targets. We defined two distinct bone-invading meningiomas and their control counterparts: 1-spheno-orbital and control sphenoid wing meningiomas and 2-transbasal and control anterior skull base meningiomas. From our database, we selected 75 patients in these two categories. RNA was extracted from paraffin-embedded tissues and used for Illumina Whole Genome DASL assay. Array data was verified using real-time PCR (RT-qPCR). We performed tissue microarray (TMA) on archived paraffin sections for immunohistochemical analysis. In vitro and in vivo functional studies were performed using meningioma cell lines (IOMMA-Lee, CH157-MN, and F5), focusing specifically on the functional relevance of MMP16 and Matrilin4 on meningioma bone invasion. Small animal MRI was used to study tumor growth patterns and invasion. RNA microarray data analysis identified 222 differentially expressed genes. We selected the most relevant and highly overexpressed genes to pursue in this study (PDGFRa, MMP16, MMP19, Matrilin4, and ADAMTS4). RT-qPCR confirmed the upregulation of these genes. TMA analysis identified elevated expression of MMP16 in inflammatory cells in invasive tumors, implying a role for inflammatory cells in the extracellular matrix remodeling of meningioma tumors. Matrilin4 was increased in a statistically significant number of bone invading meningiomas. In vitro and in vivo studies confirmed an important role for MMP16 and Matrilin4 in modulating bone invasion. These results provide novel differentially expressed proteins involved in boneinvading meningiomas that can be examined as suitable potential therapeutic targets in future studies. compared results between two AA (sunitinib or VEGF-TRAP) used in combination with RT to identify and validated MRI biomarkers of response to therapy. Mice with intracranial glioma xenografts received either no treatment or treatment with AA, RT (single dose of 8 Gy), or AA + RT (concurrent or AA following RT). Serial multiparametric MRI analyses were carried out at baseline and on treatment days 3, 7, 10, 14, and 21. Initial area under the signal intensity curve at 60 seconds (iAUC60), Ktrans, Kep, and Ve were measured for DCE-MR, and apparent diffusion coefficient (ADC) maps were analyzed for diffusion weighted imaging. Correlative immunohistological analysis of tumor growth and vascularity was performed for each time point. There was a significant reduction (70%) in Ktrans in groups treated with either AA or AA + RT (concurrent) on treatment day 3, with sustained reduction throughout treatment. A significant increase in ADC was seen in RT arms compared with non-RT arms. Correlating with Ktrans results were histological analyses of tumor vascularity demonstrating a significant reduction in microvascular density in the AA or AA + RT arms along with a reduction in vascular diameter on days 3 and 7. Similarly, a significant increase in tumor hypoxia in the AA and AA + Rt arms on treatment days 3 and 7, respectively, reflects ADC changes. These results identify novel and reproducible biomarkers of response to AA, RT, and combinatorial therapy. Future work will focus on validating these biomarkers in clinical trials for patients with malignant gliomas.
AI-27. IDENTIFICATION OF MRI BIOMARKERS AND HISTOPATHOLOGICAL ALTERATIONS IN RESPONSE
AI-28. INTRATUMORAL DELIVERY OF BEVACIZUMAB INHIBITS ANGIOGENESIS AND CANCER STEM CELLS COMPARED WITH INTRAVENOUS BEVACIZUMAB
Shering Torres, Niyati Jhaveri, Weijun Wang, Axel H. Schonthal, Stan G. Louie, Florence M. Hofman, and Thomas C. Chen; University of Southern California, Los Angeles, CA Bevacizumab is approved by the U.S. Food and Drug Administration for the treatment of recurrent glioblastoma multiforme (GBM). Although it has been demonstrated to increase patients' progression-free survival, intravenous bevacizumab administration has been associated with marked systemic side effects. Moreover, bevacizumab failure may be associated with a recurrence pattern similar to gliomatosis cerebri. To determine whether there is a role for local intratumoral administration of bevacizumab versus systemic administration, we have demonstrated that mice implanted with U-87 glioma cells intracranially had the best survival when treated with bevacizumab intratumorally compared with intravenous bevacizumab. Moreover, this survival period was enhanced when intratumoral bevacizumab was given in combination with intraperitoneal irinotecan. To identify a potential cause for this improved result using the intratumoral administration of bevacizumab, we analyzed the tumors of these animals at time of euthanasia, 14 days after treatment was discontinued. Microvessel density (MVD) analysis of the tumor tissues revealed that gliomas treated with intratumoral bevacizumab had significantly fewer tumor vessels compared with the intravenous group. Moreover, the morphology of the tumor vessels between the two groups was significantly different; the intratumorally treated gliomas had enlarged, thin vessels While the systemically treated tumors had small, narrow vessels. Immunohistochemical analysis for stromal derived factor-1 (SDF-1), a chemoattractant for bone marrowderived endothelial progenitor/stem cells, demonstrated less staining in the intratumoral bevacizumab-treated gliomas compared with systemically treated tumors. To determine the functional significance of decreased SDF-1, immunostaining was performed for aldehyde dehydrogenase 1 (ALDH1), a stem cell marker. Gliomas treated with intravenous bevacizumab had increased numbers of ALDH1-positive cells, compared with tumors treated with intratumoral bevacizumab. Our findings demonstrate that intratumoral bevacizumab administration is associated with decreased angiogenesis and fewer stem cells compared with intravenous treatment, suggesting that this new route of administration is a more effective therapy for malignant gliomas. INTRODUCTION: Due to its effects on VEGF-mediated vascular permeability, bevacizumab may decrease contrast enhancement in glioblastoma, even in the presence of continuous nonenhancing tumor progression. We report a glioblastoma patient treated with bevacizumab who developed symptoms suspicious for spinal leptomeningeal metastasis, but without corresponding radiographic changes and negative CSF cytology. CASE REPORT: The patient was a 65-year-old woman with glioblastoma who was treated with surgical resection, BCNU wafer placement, chemoradiation with temozolomide, standard adjuvant temozolomide combined with bevacizumab, and then daily temozolomide (50 mg/m 2 ) and bevacizumab. While on treatment, the patient developed progressive gait abnormalities, headaches and hydrocephalus, as well as severe back pain and signs of lumbosacral radiculopathy. Symptoms transiently improved with a ventriculoperitoneal shunt. MRI of the brain showed minor contrast-enhancing disease progression, but the spine appeared normal on MRI. CSF analysis showed increased protein (125 mg/dL) and low glucose (23 mg/dL); cytology was negative. Followup MRIs showed further progression of intracranial disease but no evidence of spinal disease. Symptoms progressed rapidly and the patient died shortly afterward. On autopsy, macroscopic examination of the spinal cord showed leptomeningeal nodularity and thickening of spinal roots and cauda equina, with tumor confirmed on microscopic examination. In the brain, there was evidence of extensive tumor progression and infiltration of cerebral hemispheres. Diffuse tumor cell infiltration beyond the apparent border of gross disease was seen; co-option of existing vessels, as previously described, was not present. CONCLUSION: This patient had prolonged symptoms and signs of spinal leptomeningeal disease, which was eventually confirmed by autopsy, but the MRI scans of the spine remained normal, suggesting a masking effect through bevacizumab-mediated anti-VEGF effects. Recognizing this pattern of tumor progression in patients receiving bevacizumab is important for optimal disease management.
AI-29. BEVACIZUMAB EFFECTS MASKING LEPTOMENINGEAL
AI-30. COMBINED IL12 AND ANTIANGIOGENIC TREATMENT OF EXPERIMENTAL CEREBRAL METASTASES
Matthias Kirsch, Klaus D. Martin, Aiko Bertram, Ortrud uckermann, Elke Leipnitz, Patrick Weigel, Achim Temme, Gabriele Schackert, and Kathrin Geiger; Universitä tsklinikum Dresden, Dresden, Germany INTRODUCTION: Experimental melanoma metastases are susceptible to antiangiogenic treatment using endogenous inhibitors of angiogenesis such as endostatin. The purpose of this study was to evaluate synthetic angiogenesis inhibitors in combination with an immunostimulatory mediator interleukin-12 (IL12) in murine models of brain metastases. METHODS: Two different murine melanoma metastases models were employed: first, a solitary tumor was induced by injection of 50,000 murine K1735 melanoma cells into the right frontal lobe; secondly, hematogenous metastases to one hemisphere were induced by injection of 100,000 cells into the right internal carotid artery of mice. The cell lines used were wild type (wt) or constitutionally overexpressing IL12. The mice were treated systemically with a thalidomide analogue, a VEGFR2 blocker, or an integrin alpha5-beta3/5 antagonist alone or in combination with IL12. RESULTS: Whereas tumors induced by direct intracerebral deposition of tumor cells largely showed a classical vascularization phenotype of sprouting angiogenesis, the hematogenous metastases relied initially on a cooption-like vascularization phenotype. Solid melanoma metastases induced by direct intracerebral injection where more susceptible to daily low-dose treatment using angiogenic compounds than multiple hematogenous metastases. Solitary metastases responded with a 30% tumor reduction compared with minimal inhibition of hematogenously induced melanoma metastases. However, after 21 days, a marked reduction of vascularity was seen in both tumor types. IL12 was effective in reducing tumor growth; however, no synergistic effects were seen. CONCLUSION: IL12 immunostimulatory treatment of experimental brain metastases does not improve the effectiveness of systemic antiangiogenic therapy. The combination of radiation therapy and temozolomide is the standard treatment for newly diagnosed glioblastoma multiforme (GBM). Increasingly, anti -vascular endothelial growth factor (VEGF) therapy is added to this treatment. However, little is known about the effects of standard chemoradiation on tumor biology and how best to incorporate anti-VEGF therapy. We evaluated changes on MRI in patients with newly diagnosed GBM during chemoradiation treatment with and without an anti-VEGF agent. METHODS: Two cohorts of patients enrolled in IRB-approved clinical trials underwent serial MRI scans at baseline prior to chemoradiation, weekly during 6 weeks of chemoradiation, then 2 -4 weeks following the completion of chemoradiation. One cohort received radiation and temozolomide while the second cohort also received cediranib, a pan-VEGF receptor tyrosine kinase inhibitor. RESULTS: Eight patients were treated with standard chemoradiation and 39 patients were treated with standard chemoradiation plus cediranib. The median percent changes from baseline in volume of contrast enhancement for the standard chemoradiation group vs. the group treated with chemoradiation plus cediranib were 10.13% vs. -24.32% (week 1), One of the major tyrosine kinase receptors involved in the control of the glioma environment is Tie2. Although Tie2 was thought to be an exclusive membrane receptor in endothelial cells, our group reported its expression in glioma cells, including brain cancer stem cells. In this population, Tie2 finely regulates the transcription of several ABC transporters mediating the multidrug resistance phenotype of gliomas. Because Tie2 induces transcriptional activity, we sought to determine whether Tie2 is localized in the nucleus of glioma cells. Immunofluorescence showed that Tie2 localized in the nucleus of cells upon treatment with the Tie2 ligand, Ang1. Accordingly, decrease of Tie2 expression from the cellular membrane was assessed by FACS analysis. We observed that treatment with Ang1 and Ang2 had different effect in the subcellular localization of Tie2. Thus, timepoint and dose-dependent assays showed that treatment with Ang1 (,400 ng/mL,15 min) or with a high dose of Ang2 (.800 ng/ mL,15 min), resulted in the localization of Tie2 in the nucleus of cells. Using N-and C-terminus antibodies, our studies also indicated that Tie2 is found as a full-length protein in the nuclear compartment, and, importantly, that it is phosphorylated (Tyr992). Analyses of Tie2 protein revealed the presence of a nuclear localization signal (aa 579-585:RRSVQKS). Interestingly, chromatin immunoprecipitation assays demonstrated that expression of Tie2 in the nucleus correlates with its presence in transcriptional complexes that are related to cell viability. In vivo studies showed that Tie2 was present in the nucleus of glioma cells of brain tumor stem cell -derived intracranial xenografts. In summary, we provide for the first time evidence that the receptor tyrosine kinase Tie2 is found in the nuclear compartment and that its trafficking is ligand dependent. We speculate that nuclear Tie2 possesses distinct biological functions and that these might be key to the cellular interactions in the tumor niche and chemoresistance. Tumor-associated microglia and macrophages (TAMs) constitute a large portion (10% -30%) of the cellular components of glioblastoma, and it is thought that they contribute to glioma progression. However, little is known about the interactions between TAMs and glioma cells that may promote tumor growth and invasion. We have developed a PDGF-driven rodent model of glioma that induces glial progenitors to form tumors that closely resemble human glioblastomas, while also expressing green fluorescent protein (GFP). Time-lapse microscopy of slice cultures generated from this model allows one to monitor the migration of glioma cells as they invade the surrounding brain tissue. Here, we extend our analysis to image the migration and behavior of microglia, both within and outside the tumor microenvironment. Slice cultures prepared from the resulting tumors were incubated with rhodamine conjugated isolectin B4 to label microglia and then imaged in normoxic conditions by two-color fluorescence time-lapse microscopy. The migratory behavior of GFP+ glioma cells and rhodamine+ microglia was analyzed within the tumor and in the surrounding brain tissue. Our results showed that microglia within the center of the tumor and at the infiltrative margins moved with greater speed but less directionality, than did the GFP+ glioma cells. In contrast, microglia in areas of brain that were not infiltrated by glioma cells showed very little cell movement. Furthermore, incubation of the slices with the cytokine stromal derived factor (SDF1) induced a marked increase in the migratory speed of the microglia within the tumor but had little effect on the movement of GFP+ glioma cells or microglia outside the tumor. These results suggest that SDF1 plays a role in stimulating microglia within gliomas and that blocking SDF1 signaling may be an effective way of inhibiting the tumor-promoting actions of TAMs.
AI-31. COMPARISON OF CHANGES IN MRI CONTRAST ENHANCEMENT AND FLAIR HYPERINTENSITY IN PATIENTS
AI-34. FULL-LENGTH WILD-TYPE CD99 INCREASES THE MIGRATION AND INVASIVENESS OF HUMAN MALIGNANT GLIOMA CELLS
Jong Hee Chang, Ho Jun Seol, Adrienne Weeks, Christian A. Smith, and James T. Rutka; The Hospital for Sick Children, Toronto, ON, Canada
The malignant glioma is the most common primary human brain tumor, and its migration and invasiveness away from the primary tumor mass is considered a leading cause of tumor recurrence and treatment failure. Recently, gene expression profiling revealed that CD99, a transmembrane glycoprotein, is more expressed in malignant glioma than in normal brain. CD99 has been implicated in cell adhesion and migration in various cells, even though the function of this gene is not understood clearly. This gene has two isoforms: wild-type and splicing variant. Several investigators suggest that wild-type CD99 may be an oncosuppressor in some tumors, as opposed to the splicing variant. Nonetheless, our RT-PCR and Western blot analyses revealed that only wild-type CD99 is expressed in human glioma cells and tissues. In addition, through MTS, colony-forming, and anoikis assays, we found that wild-type CD99 in glioma cells has enough resistance to anoikis and ability to survive and grow in anchorage independence, as opposed to previous reports in other tumors. Using immunohistochemistry within a tissue microarray, we validated that CD99 demonstrates higher expression in gliomas compared with nonneoplastic brain. To assess the role of CD99 in glioma migration and invasion, we inhibited CD99 expression by siRNA and demonstrated decreased glioma cell migration and invasion. In contrast, when CD99 was overexpressed in glioma cells, we observed enhancement of cell migration and invasiveness. An orthotopic brain tumor model with nude mice harboring CD99-overexpressing glioma cells resulted in a significantly decreased survival rate compared with control mice. Moreover, higher invasiveness was observed in the CD99-overexpressing mice on pathological review. Taken together, our findings suggest that CD99 plays an important role in the migration and invasion of human gliomas. CD99 could be a target to inhibit migration and invasion, especially in CD99-expressing gliomas. Glioblastoma multiforme (World Health Organization grade 4 glioma; GBM) are highly vascular, infiltrative tumors with 12-15 -month median patient survival. Standard treatment with surgical resection, radiation, and chemotherapy provides only a modest survival benefit. Since GBM are infiltrative, local therapies do not remove all neoplastic elements, and appropriate therapeutic alternatives for infiltrative cells are not available. This project addresses a potential therapeutic target, the water channel protein aquaporin 1 (aqp1). Literature suggests expression of the aquaporin 1 (AQP1) gene correlates negatively with patient survival and links it to cell movement. Our clinical data indicate glioma expression of AQP1 RNA and aqp1 protein are independently prognostic. We developed in vitro and in vivo assays to model likely mechanisms underlying the clinical effects of aqp1. Our in vitro assays showed that aqp1 alters the motility and invasiveness of GBM. Our in vivo experiments with rodent orthotopic xenografts showed that aqp1 expression increases diffuse infiltration and invasion of GBM. These
